Клинико-морфологическая, иммуногистохимическая характеристика и критерии прогноза гастроинестинальных стромальных опухолей
Диссертация
Проведено ретроспективное исследование 36 GIST, отобранных по гистологическим и иммуноморфологическим критериям, прежде всего, экспрессии CD117. Женщин было 20 (55,6%), мужчин — 16 (44,4%), возраст больных составил от 23 до 90 лет (в среднем — 68,7±17,1 лет) и у женщин был в 1,2 больше, чем у мужчин (71,3±15,3 против 59,4±11,2 лет). Длительность наблюдения за больными после оперативных… Читать ещё >
Список литературы
- Анурова О.А., Снигур П. В., Филиппова Н. А., Сельчук В. Ю. Морфологическая характеристика стромальных опухолей желудочно-кишечного тракта. // Архив патологии. — 2006. — Вып. 1. — С. 10−14.
- Анурова О.А. Морфологическая и иммуногистохимическая диагностика гастроинтестинальных стромальных опухолей желудочно-кишечного тракта (GIST). //Современная онкология (экстравыпуск). — 2007. — С. 79−100.
- Братанчук С.Ю., Мацко Д. Е., Имянитов Е. Н. и соавт. Гастроинтестинальная стромальная опухоль пищевода. //Архив патологии. — 2007. — Вып. 1. — С. 47−49.
- Казанцева И.А. Морфологические особенности GIST. //Современная онкология (экстравыпуск). — 2007. — С. 50−79.
- Никулин М.П., Стилиди И. С. Гастроинтестинальные стромальные опухоли (GIST). Эпидемиология, диагностика, современные подходы в лечении. //Современная онкология (экстравыпуск). — 2007. — С. 3−50.
- Пальцев М.А. Введение в молекулярную медицину. — М.: Мед., 2004.
- Appelman Н., Helwig Е. Gastric epithelioid leiomyoma and leiomyosarcoma (leiomyoblastoma). // Cancer. — 1976. —38. —P.708−728.
- Appelman H. Smooth muscle tumors of the gastrointestinal tract: What we know now that Stout didn’t know. // Am. J. Surg. Pathol. — 1986. — 10(Suppl 1). — P.83−99.
- Appelman H. Mesenchymal tumors of the gut: Historical perspectives, new approaches, new results and does it make any difference? // Monogr. Pathol. — 1990.—31. —P.220−246.
- Berman J., O’Leary T. Gastrointestinal stromal tumor workshop. // Hum Pathol — 2001.—32.—P.578−582.
- Brizzi M., Dentelli P., Rosso A. STAT protein recruitment and activation in c-kit deletion mutants. // J Biol Chem. — 1999. — 274. — P.16 965−16 972.
- Broudy V. Stem sell factor and hematopoiesis. // Blood. — 1997. —90. — P.1345−1364.
- Carney J. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial occurrence. // Mayo Clin Proc. — 1999. —74. — P.543−552.
- Carney J., Stratakis C. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. //Am J Med Genet. —2002. — 108. — P.132−139.
- Catena F., Pasqualine E., Campione O. Gastrointestinal stromal tumors: experience of an emergency surgery department. // Dig Surg. — 2000. — 17. — P. 503−507.16. .Ciaparrone M., Yamamoto H., Yao Y. et al. // Cancer Res. 1998. — 58. -P.l 14−122.
- Chetty R. p27 protein and cancers of the gastrointestinal tract and liver: an overview. // J Clin Gastroenterol. — 2003. —37. — P.23−27.
- Clary B., DeMatteo R., Lewis J., et al. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. //Ann Surg Oncol. — 2001. — 8. — P.290−299.
- Cooper P., Quirke P., Hardy G., Dixon M. A flow cytometric, clinical, and histological study of stromal neoplasms of the gastrointestinal tract. // Am J Surg Pathol. — 1992.— 16. — P.163−170.
- Corless C., McGreevey L., Haley A., et al. KIT mutation are common in incidental gastrointestinal tumors one centimeter or less in size. //Am J Pathol. — 2002.—160. —P.1567−1572.
- Crosby J., Catton C., Davis A., et al. Malignant gastrointestinal stromal tumors of the small intestine: A review of 50 cases from a prospective database. //Ann Surg Oncol. — 2001. — 8. — P.50−59.
- Cunningham R., Abbondanzo S., Chu W. s Emory T., Sobin L., O’Leary T. Apoptosis, bcl-2 expression, and p53 expression in gastrointestinal stroma/smooth muscle tumors. //Appl Immunohistochem Mol Morphol. —2001. — 9. — P. 19−23.
- Cunningham R., Federspiel B., McCarthy W., Sobin L., O’Leary T. Predicting prognosis of gastrointestinal smooth muscle tumors. Role of clinical and histologic evaluation, flow cytometry, and image cytometry. // J Surg Path. — 1993. — 17. —P.588−594.
- Debiec-Rychter M., Lasota J., Sarlomo-Rikala M., Kordek R., Miettinen M. Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. //Cancer Genet Cytogenet. — 2001. —128. — P.24−30.
- DeMatteo R., Lewis J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. //Ann Surg. — 2000.—231. —P.51−58.
- El-Rifai W., Sarlomo-Rikala M., Mirttinen M., et al. DNA copy number losses in chromosome 14- an early change in gastrointestinal stromal tumors. // Cancer Res. —1996. —56. — P.3230−3233.
- El-Rifai W., Sarlomo R., Andersson L., Miettinen M., Knuutila S. DNA copy number changes in gastrointestinal stromal tumors a distinct genetic entity. // Ann Chir Gynaecol. — 1998. — 87. — P.287−290.
- Emory T., Derringer G., Sobin L., O’Leary T. Ki-67 (MIB-1) immunohistochemistry as a prognostic factor in gastrointestinal stromal tumors. // J Surg Pathol. — 1997. — 2. — P.239−242.
- Emory T., Sobin L., Lukes L., et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. // Am J Surg Pathol. — 1999.—23. —P.82−87.
- Erickson L., Yousef O., Jim L. et al. p27Kipl expression distinguishes papillary hyperplasia in Grave’s disease from papillary thyroid carcinoma. // Modern pathology. — 2000. —13. — P. 1014−1019.
- Ernst S., Hubbs A., Przygodzki R., et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. // Lab Invest. — 1998. —78. — P.1633−1636.
- Evans H. Smooth muscle tumors of the gastrointestinal tract: a study of 56 cases followed for a minimum of 10 years. // Cancer. —1985.—56.—P.2242−2250.
- Feakins R., Mulcahy H., Quaglia A. et al. // Cancer. 2000. — 89. — 8. — P.1684−1691.
- Fero M., Randel E., Gurley K. The murine gene p27kipl is haplo-insufficient for tumor suppression. // Nature. — 1998. — 396. — P.177−180.
- Fillies T., Woltering M., Brandt B., Van Diest J., Werkmeister R., Joos U., Buerger H. Cell cycle regulating proteins p21 and p27 in prognosis of oral squamous cell carcinomas. // Oncol Rep. — 2007. —17. —2. — P.355−359.
- Fletcher C., Berman J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. // Human Pathol. — 2002. —33. — P.459−465.
- Fong Y., Coit D., Woodruff J., et al. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. // Ann Surg. — 1993. —217. — P.72−77.
- Franquemont D., Frierson-HF J. Muscle differentiation and clinicopathologic features of gastrointestinal stromal tumors. // Am J Surg Path. — 1992. —16. — P.947−954.
- Franquemont D. Differentiation and risk assessment of gastrointestinal stromal tumors. // Am J Clin Pathol. —1995. —103. — P.41−47.
- Fritz A., Percy C., Jack A. et al. International Classification of Diseases for Oncology (ICD-O). — 3rd ed. — WHO, Geneve, 2000
- Fukasawa T., Chong J., Sakurai S. et al. Allelic loss of 14q and 22q, NF Mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumors. // Jpn J Cancer Res.— 2000.—91.—P.1241−1249.
- Gelen T., Elpek G., Aksoy N., Ogus M., Keles N. p27 labeling index and proliferating gastrointestinal stromal tumors: correlations with clinicopathologic factors and recurrence. // Jap J Clin Oncol. — 2003. — 33. — P.346−352.
- Goldblum J., Appelman H. Stromal tumors of the duodenum: A histologic and immunohistochemical study of 20 cases. // Am J Surg Pathol. —1995. —19. — P.71−80.
- Grana X., Reddy P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin dependent kinase inhibitors (CDIs). // Oncogene,. —1995. —11. — P.211−219.
- Guan K., Jenkins C., Li Y. Growth suppression by pl8, pl6 and pl4 related CDK6 inhibitor, correlates with wild-type Rb function. // Genes Dev. — 1994. — 8. —P.2939−2952.
- Hamilton S., Aaltonen L. (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. — IARC Press, Lyon, 2000.
- Hannon G., Beach D. pi is a potential effector of TGF induced cell cycle arrest. //Nature. — 1994. —371. —P.257−261.
- Harper J., Adami G., Wei N., et al. The p21kd Cdk interactin protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. //Cell.—1993—75—P.805−816.
- Hasegawa T., Matsuno Y., Shimoda T., Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. // Hum Pathol. — 2002. — 33. —P.669−676.
- Heinrich M., Blanke C., Druker B., et al. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. // J Clin Oncol. — 2002. — 20. — P. 1692−1703.
- Heinrich M., Corless C., Demetri G., et al. KIT and PDGFRA mutations predict imatinib mesylate response. // J Clin Oncol.—2003.— 21. — P.4342−4349.
- Heinrich M., Corless C., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. // Science.—2003.—299.—P.708−710.
- Hemesath T., Price E., Takemoto C., et al. MAP kinase links the transcription factor Microphthalmia to c-kit signaling in melanocytes. // Nature. — 1998. — 391. —P. 298−301.
- Herrera G., Cerezo L., Jones J., et al: Malignant small bowel neoplasm of enteric plexus derivation (plexosarcoma). Light and electron microscopic study confirming the origin of the neoplasm. // Dig Dis Sei. —1984. — 29 — P.275−284.
- Hillemanns M., Pasold S., Bottcher K., Hofler H. Prognostic factors of gastrointestinal stromal tumors of the stomach. // Verh Dtsch Ges Pathol. — 1998.82. —P.261−266.
- Hirai H., Roussel M., Kato J. et al. Novel INK4 protein pl9 and pl8, are specific inhibitors of the cyclin D-dependent kinase CDK4 and CDK6. // Mol. Cell Biol. — 1995. — 15. — P.2672−2681.
- Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. // Science. — 1998. — 279. — P.577−580.
- Hirota S., Nishida T., Isozaki K., et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. // J Pathol. — 2001.—193. — P.505−510.
- Hirota S., Ohashi A., Nishida T., et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. // Gastroenterology. — 2003. —125. — P.660−667.
- Honjo S., Kase S., Osaki M. et al. COX-2 correlates with F-box protein, Skp2 expression and prognosis in human gastric carcinoma. // Int J of Oncology. -— 2005. — 26. —2. — P.353−360.
- Hornick J., Fletcher C. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. // Am J Clin Pathol. —2002. —117.1. P.188−193.
- Joensuu H., Dimitrijevic S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumors. // Ann Med. — 2001. — 33. — P.451−455.
- Joensuu H., Kindblom L. Gastrointestinal stromal tumors — a review. // Acta Orthopaedica Scandinavica. — 2004. —75 (Supplement 311). —P.62−71.
- Joensuu H., Roberts P., Sarlomo-Rikala M., et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. //N Engl. J Med. — 2001. —344. — P. 1052−1056.
- Kim D., Lee H., Nam E., et al. Reduced expression of the cell-cycle inhibitor p27Kipl is associated with progression and lymph node metastasis of gastric carcinoma. // Histopathology. — 2000. —36. —3. — P.245−251.
- Kim N., Kim J., Ahn J., Seong C., Noh S., Kim C., Min J., Kim H. Putative chromosomal deletions on 9P, 9Q, and 22Q occur preferentially in malignant gastrointestinal stromal tumors. // Int J Cancer. — 2000. — 85. — P.633−638.
- Kindblom L., Remotti H., Aldenborg F., et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. // Am J Pathol. —1998. —153. — P. 1259−1269.
- Kindblom L.-G., Meis-Kindblom J., Bumming P., et al. Incidence, phenotypic and biologic spectrum of gastrointestinal stromal tumors (GIST)-a population based study of 600 cases. // Ann Oncol. — 2002. —13 (suppl.5. abstract 5770).
- Kinoshita K., Hirota S., Isozaki K., et al. Absence of c-kit genemutations in gastrointestinal stromal tumors from neurofibromatosis 1 patiens. // J Pathol. — 2004.—202. —P.80−85.
- Kinsel L., Szabo E., Green G., et al. Immunohistochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. // Cancer Res. — 1989. — 49. — P. 1052−1056.
- Kitamura Y., Hirota S., Nishida T. Molocular pathology of c-kit proto-oncogene and development of gastrointestinal stromal tumors. //Ann Chir Gynaecol. — 1998. — 87. — P.282−286.
- Lasota J., Jasinski M., Sarlomo-Rikala M., et al. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. // Am J Pathol. —1999. —154.1. P.53−60.
- Lasota J., Carlson J., Miettinen M. Spindle cell tumor of urinary bladder serosa with phenotypic and genotypic features of gastrointestinal stromal tumor. // Arch Pathol Lab Med. — 2000. —124. — P.894−897.
- Lasota J., Wozniak A., Sarlomo-Rikala M., et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors: a study of two hundred cases. //Am J Pathol. — 2000. — 157. P. 1091−1095.
- Lasota J., Dansonka-Meiszkowska A., Sobin L., et al. A great majority of GISTs with PDGFRA mutations represent gastric tumors with low or no malignant potential. // Lab Invest. — 2004. — 84. — P.874−883.
- Lauwers G., Erlandson R., Casper E., et al: Gastrointestinal autonomic nerve tumors: A clinicopathologic, immunohistochemical and ultrastructural study of 12 cases. // Am J Surg Pathol. — 1993. — 17. — P.887−897.
- Lee M., Reynisdottir I., Massague J. Cloning of p27Kipl, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. // Genes Dev.1995. —9. —P.639−649.
- Lee J., Joshi V., Griffin J., et al: Gastrointestinal autonomic nerve tumor: Immunohistochemical and molecular identity with gastrointestinal stromal tumor. // Am J Surg Pathol. —2001. — 25. — P.979−987.
- Lerma E., Oliva E., Tugues D., Prat J. Stromal tumors of gastrointestinal tract: a clinicopathological and ploidy analysis of 33 cases. // Virchows Arch. — 1994. — 424. —P. 19−24.
- Liu X., Kawauchi S., Oga A., et al. // Histopatology. 2001. — 6. — P.603−610.
- Lloyd R., Ericson L., Jin L., Kulig E., Qian X., Cheville J., Scheithauer B. p27kipl: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. // Am J Pathol. — 1999. — 154. — P.313−323.
- Loda M., Cukor B., Tam S., lavin P., Fiorentino M., Draetta G., Jessup J., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. // Nat Med. — 1997. — 3. —P.231−234.
- Lois A., Cooper L., Geng Y. et al. Expression of the pi6 and pi5 cyclin-lymphocyte dependent kinase inhibitors in activation and neuronal differentiation. // Cancer res. — 1995. — 55. —18. — P.4010−4013.
- Lux M., Rubin B., Biase T., et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. // Am J Pathol. — 2000. — 156. — P.791−795.
- Mazur M., Clark H. Gastric stromal tumors: Reappraisal of histogenesis. // Am J Surg Pathol. —1983. — 7. — P.507−519.
- Miettinen M., Virolainen M., Sarlomo-Rikala M. Gastrointestinal stromal tumors: Value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. // Am J Surg Pathol. — 1995. — 19. — P.207−216.
- Miettinen M., Sarlomo-Rikala M., Lasota J. Gastrointestinal stromal tumors: Recent advances in understanding of their biology. // Hum Pathol. — 1999. — 30. — P.1213−1230.
- Miettinen M., Sarlomo-Rikala M., Sobin L., et al: Esophageal stromal tumors: A clinicopathologic, immunohistochemical and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas.
- Am J Surg Pathol. —2000. — 24. — P.211−222.
- Miettinen M., Sobin L., Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). // Mod Pathol. — 2000. — 13. — P. 1134−1142.
- Miettinen M., Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. //Virchows Arch. —2001. — 438. — P. 1−12.
- Miettinen M., Soin L., Lasota J. Gastrointestinal Stromal Tumors of the Stomach: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 1765 Cases With Long-term Follow-up. // Am J Surg Pathol. —2005. — 29. —P.52−68.
- Mikhael A., Bacchi C., Zarbo R., et al: CD34 expression in stromal tumors of the gastrointestinal tract. // Appl Immunohistochem. — 1994. — 2. —P.89−93.
- Min K.-W. Small intestinal stromal tumors with skeinoid fibers. Clinicopathological, immunohistochemical and ultrastructural investigations.
- Am J Surg Pathol. —1992. — 16. — P. 145−155.
- Monihan J., Carr N., Sobin L. CD34 immunoexpression in stromal tumors of the gastrointestinal tract and in mesenteric fibromatosis. // Histopathology. — 1994. —25. —P.469−473.
- Mori M., Mimori K., Shiraishi T., et al. p27 expression and gastric carcinoma. //Nat. Med. — 1997. — 3. — P.259.
- Nakahara M., Isozaki K., Hirota S., Miyagawa J., Hase S., Taniguchi M., Nishida T., Kanayama S., Kitamura Y., Shinomura Y., Matsuzawa Y. A novel gain-of-fimction mutation of c-kit gene in gastrointestinal stromal tumors.
- Gastrointerology. — 1998. — 115. — P. l 090−1095.
- Newman P., Wadden C., Fletcher C. Gastrointestinal stromal tumours: Correlation of immunophenotype with clinicopathologic features. // J Pathol. — 1991. —164. —P.107−117.
- Ng E., Pollock R., Munsell M., et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas: implications for surgical management and staging. // Ann Surg. — 1992. — 215. — P.68−77.
- Nishida T., Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. // Histol Histopathol. — 2000. — 15. — P.1293−1301.
- O’Leary T., Berman J. Gastrointestinal stromal tumors: Answers and questions. // Human Pathol. — 2002. — 33. — P.466−469.
- Ortiz-Hidalgo C., de Leon Bojorge B., Albores-Saavedra J. Stromal tumor of the gallbladder with phenotype of interstitial cells of Cajal. A previously unrecognized neoplasm. // Am J Surg Pathol. — 2000. — 24. — P. 1420−1423.
- Panizo-Santos A., Sola I., Vega F., de Alava E., Lozano M., Pardo-Mindan J. Predicting metastatic risk of gastrointestinal stromal tumors: role of cell proliferation and cell cycle regulatory proteins. // Int J Surg Pathol. — 2000. — 8.1. P.133−144.
- Peschos D., Stefanou D., Vougiouklakis T., Assimakopoulos D.A., Agnantis N.J. Cell cycle proteins in laryngeal cancer: role in proliferation and prognosis. // J Exp Clin Cancer Res. — 2005. — 24. — 3. — P.431−437.
- Pidhoresky I., Cheney R., Krybill W., et al. gastrointestinal stromal tumors: current diagnosis biologic behavior, and management. // Ann Surg Oncol. — 2000.7. —P.705−712.
- Polyak K., Kato J., Solomon M., et al. p27Kipl, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.
- Genes Dev. — 1994. — 8. — 1. — P.9−22.
- Polyak K., Lee M., Erdjument-Bromage H., et al. Cloning of p27Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. // Cell. — 1994. — 78. — 1. — P.59−66.
- Pruneri G., Mazzarol G., Fabris S., Del Curto B., Bertolini F., Neri A., Viale G. Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation.
- Mod Pathol. — 2003. — 16. — P.886−8892.
- Ranchod M., Kempson R. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: A pathologic analysis of 100 cases. // Cancer. —1977. — 39.1. P.255−262.
- Reith J., Goldblum J., Lytes R., et al. Extragastrointestinal (soft tissue) stromal tumors: An analysis of 48 cases with emphasis on histologic predictors of outcome. // Mod Pathol. —2000. — 13. — P.577−585.
- Rubin B., Fletcher J., Fletcher C. Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors. // Int J Surg Pathol. —2000. — 8.1. P.5−10.
- Rubin B., Singer S., Tsao C., et al: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. // Cancer Res. —2001. — 61. — P.8118−8121.
- Rudolph P., Gloeckner K., Parwaresch R., et al. Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: A multivariate clinicopathologic study. // Hum Pathol. — 1998. — 29. — P.791−800.
- Sarlomo-Rikala M., Kovatich A., Barusevicius A., et al: CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. // Mod Pathol. — 1998— 11. — P.728−734.
- Schaldenbrand J., Appelman H. Solitary solid stromal gastrointestinal tumors in von Recklinghausen’s disease with minimal smooth muscle differentiation. // Hum Pathol. — 1984— 15. — P.229−232.
- Seidal T., Edvardsson H. Expression of c-kit (CD 117) and Ki-67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumors. // Histopathology. — 1999. — 34. — P.416−4124.
- Serrano M., Hannon G., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D / CDK4. // Nature. — 1993. — 366.1. P.704−707.
- Sgambato A., Zhang Y.-Z., Arber N., Hibshoosh H., Doki Y., Ciapronne M., Santella R., Cittadini A., Weinstein I.B. Deregulated expression of p27K, pl in human breast cancers. // Clinical Cancer Research. — 1997. — 3. — P. 1879−1887.
- Sherr C., Roberts J. Inhibitors of mammalian G1 cyclin-dependent kinases. // Genes Dev. — 1995. — 9. — P. l 149−1163.
- Shiu M., Farr G., Papachristou D., et al. Myosarcomas of the stomach: natural history, prognostic factors and management. // Cancer.—1982.— 49. —P. 177−187.
- Singer S., Rubin B., Lux M., et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. // J Clin Oncol. — 2002. — 20. — P.3898−3905.
- Sircar K., Hewlett B., Huizinga J., et al: Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. // Am J Surg Pathol. —1999—23. —P.377−389.
- So J., Samarasinge K., Rajui G., et al. Expression of cell-cycle regulators p27 and cyclin E correlates with survival in gastric carcinoma patients. //Journal of surgical research. — 2000. — 94. — 1. — P.56−60.
- Taniguchi M., Nishida T., Hirota S., et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. // Cancer Res. — 1999. — 59. — P.4297−4300.
- Tavassoli F. Immunocytochemical determination of ER and PR. / In: ed. Tavassoli F.A. Pathology of the breast. — Second edition, Appleton and Lange, USA, 1999. —P.53.
- Thomas R., Sobin L. Gastrointestinal cancer incidence and prognosis by histologic type, SEER population-based data 1973−1987. // Cancer. —1995. —75.1. P.154−170.
- Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. // Cell. — 1994. — 78. — 1. —P.67−74.
- Trupiano J., Stewart R., Misick C., et al. Gastric stromal tumors: a clinicopathologic study of 77 cases with correlation of features with nonaggressive and aggressive behaviors. // Am J Surg Pathol. — 2002. — 26. — P.705−714.
- Tsihlias J., Kapusta L., Singerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. // Annu. Rev. Med. — 1999.50. —P.401−423.
- Tworek J., Appelman H., Singleton T., et al: Stromal tumors of the jejunum and ileum. // Mod Pathol. —1997. — 10. — P.200−209.
- Tworek J., Goldblum J., Weiss S., et al: Stromal tumors of the abdominal colon: A clinicopathologic study of 20 cases. // Am J Surg Pathol. — 1999. — 23.1. P.937−945.
- Tworek J., Goldblum J., Weiss S., et al. Stromal tumors of the anorectum: A clinicopathologic study of 22 cases. // Am J Surg Pathol. — 1999. — 23. — P.946−954.
- Van-de-Rijn M., Hendricson M., Rouse R. CD34 expression by gastrointestinal stromal tumors. // Hum Path. — 1994. — 25. — P.766−771.
- Van den Abbeele A. F18-FDG-PET provides early evidence of biological response to STI571in patients with malignant gastrointestinal stromal tumors (GIST). // Proc Am Assos Clin Oncol. — 2001. — 20. — 362a (abstract).
- Van Oosterom A., Judson I., Verweij J., et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. // Lancet.2001. — 358. — P.1421−1423.
- Vidal A., Koff A. Cell-cycle inhibitors: three families united by a common cause. // Gene. — 2000. — 247. — P. 1−15.
- Weidner N., et al. Modern surgical pathology. 1st edition. — Elsevier Sgience, USA, 2003. —P.1787.
- Weiler S., Мои S., DeBerry C., et al. JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor.
- Blood. — 1996. — 87. — P.3688−3693
- Weiss L., Stricler J., Medeiros L., et al. Proliferative rates of non-Hodgkin lymphomas as assessed by Ki-67 antibody. // Human Pathol. — 1987. — 18. — P.1155−1159.
- Weiss S., Goldblum J. Extragastrointestinal stromal tumors. /Weiss SW, Goldblum JR. (eds). Enzinger and Weiss’s Soft Tissue Tumors, 4th ed. St. Louis, MO, Mosby, 2001. — P.749−768.
- Wong N., Young R., Malcolmson R., et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. // Histopathology. — 2003. — 43. — P.118−126.
- Xiangming C., Natsugoe S., Takao S., et al. The cooperative role of cyclin E in the progression of advanced gastric carcinoma. // Cancer. — 2000. — 89. — 6. — P.1214−12 119.
- Xiu Yan Silvia Xie, Carter N., Darwin P., Drachenberg С. Gastrointestinal stromal tumours: update. // Архив патологии. — 2004. — Вып. 2. — C.36−40.
- Yarden Y., Kuang W., Yang-Feng Т., et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. // EMBO J. — 1988. —6. —P.3341−3351.